Cardiovascular Systems (CSI), stated that the first patients in Germany have been treated with its Stealth 360 Peripheral Orbital Atherectomy System (OAS).
The German cases represent the first commercial use of Peripheral OAS in Europe.
St. Vincenz Hospital Radiology Department head, Tobias Achenbach, where the first patients in Germany were treated by his colleagues Reza Asady and Ingo Benz said: “CSI’s minimally invasive orbital atherectomy technology allows physicians to gently modify calcified plaque and enables peripheral revascularization for patients with severely calcified arteries. The introduction of orbital atherectomy in Germany greatly improves the treatment options for my patients suffering from peripheral artery disease, or PAD.”
Dierk Scheinert, Head of the Department of Medicine, Angiology and Cardiology, Park-Krankenhaus Leipzig, and Head Department of Angiology, University Hospital Leipzig Heart Center, Leipzig, Germany said: “Of those suffering from PAD, many progress to critical limb ischemia, or CLI, the most severe and potentially deadly form of PAD. If left untreated, CLI can lead to amputation. The unique ability of orbital atherectomy to safely treat calcified peripheral lesions, both above and below the knee, will allow physicians in Germany to help a very challenging patient population.”
CSI chairman, president and CEO Scott Ward said: “By leveraging our international distribution partner, OrbusNeich, we are demonstrating our ability to rapidly introduce our OAS technology to physicians worldwide. We look forward to training many more physicians that share our passion for improving the outcomes of patients suffering from peripheral and coronary artery disease.”
In July this year, CSI announced that it had signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside of the United States and Japan.
Source: Company Press Release